However, naproxen has been associated with an increased risk of GI bleeding, compared with rofecoxib
, in one study, the authors noted.
The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial (62) was designed to investigate the GI safety of rofecoxib
in patients with RA.
This can hopefully prevent repeat performances of the rofecoxib
debacle, which lead to unprecedented confusion about the safety of all anti-inflammatory agents, especially the COX-2 inhibitor group of medications.
Celecoxib increased the risk of heart attack by 21 per cent, while rofecoxib
increased the risk by 32 per cent.
That falls to one in 695 of those on rofecoxib
and one in 1005 on ibuprofen.
US Drug Safety chief Dr David Graham said: 'Between 88,000140,000 excess cases of serious coronary heart disease probably occurred in the US over the market life of rofecoxib
We have recently reported a 6-week double-blind pilot study comparing an aqueous extract of Harpagophytum (Doloteffin[R]) and rofecoxib
in the treatment of exacerbations of chronic low back pain (Chrubasik et al.
Dr Trevor Gooding, the head of locality GP prescribing in north Warwickshire, said doctors in the area had been "particularly examining" Rofecoxib
The institute says Merck's DTC advertising bill for the COX-2 inhibitor rofecoxib
(Vioxx) totalled USD $161 million in 2000.
Cyclooxygenase-2 (Cox-2) inhibitors, such as rofecoxib
(Vioxx) and celecoxib (Celebrex), are newer agents that may prove to be safer alternatives to NSAIDs in the treatment of chronic pain.
Acetaminophen (Tylenol), rofecoxib
(Vioxx) and diclofenac sodium showed no effect on aspirin's effectiveness.
A second Yale study revealed the safety and effectiveness of a COX-2 inhibitor, rofecoxib
, as a surgical pain reliever.